Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma
NCT04151667Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Nov 2019
- Primary completion
- Nov 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of daratumumab in multiple myeloma (MM) (3 arms), sponsored by Moffitt Cancer Center. Primary endpoint: Overall Response Rate at 8 months. Started Nov 2019; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04151667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04151667.